MACH7 TECHNOLOGIES LIMITED — Board/Management Information 2023

Sep 21, 2023

ASX Announcement

==> picture [104 x 26] intentionally omitted <==

22 September 2023

BOARD OF DIRECTORS CHANGES

Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a company specialising in innovative medical imaging software solutions, announces that Mr Philippe Houssiau will retire as Non-Executive Director of Mach7, effective from the close of the Company’s Annual General Meeting on 16 November 2023 and that Ms Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company’s Annual General Meeting on 16 November 2023.

Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company’s Remuneration and Nomination Committee. In his time at Mach7 Philippe has contributed with his deep industry knowledge, expertise and strategic insights of the global healthcare IT marketplace, as both a Managing Director and as a Non-Executive Director to help guide the business in its success over the past two and a half years.

As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at ASX listed building materials company CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment.

Mach7 Managing Director, Mr. Mike Lampron noted: “ On behalf of the Company and my fellow directors, I’d like to sincerely thank Philippe for his contribution, and strategic guidance. His industry knowledge, expertise and networks, which supported the Company’s recent growth and successes, was greatly appreciated.

I’m delighted that Rebecca has agreed to join the Board. Her broad experience and understanding of the Company as well as the ASX will be greatly beneficial to the company. We look forward to working with her and utilizing her talents.”

Released on authority of the Board by:

Mike Lampron Managing Director and Chief Executive Officer

For more information, contact:

Investor Relations:

Francoise Dixon +61 (0) 412 292 977 ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Diagnostic Workflow applications. Mach7’s Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. In July 2020, Mach7 acquired Client Outlook and the eUnity Enterprise Diagnostic Viewing technology to augment Mach7’s Enterprise Data Management and Diagnostic Workflow applications. eUnity is a zero-footprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This offers healthcare professionals consolidated access to all patient images and data, ensuring clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the company also gives customers independence to deploy its solutions either on a component basis or in a unified comprehensive platform. Mach7 has built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit Mach7t.com.

==> picture [150 x 12] intentionally omitted <==

==> picture [150 x 11] intentionally omitted <==

==> picture [150 x 12] intentionally omitted <==

==> picture [150 x 11] intentionally omitted <==

==> picture [150 x 11] intentionally omitted <==

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Level 4, 96 – 100 Albert Road, South Melbourne, VIC 3205 T: +61 3 9692 7222 www.mach7t.com